Physician profile
Tara C Mitchell
NPI 1982850558
$88,841.30
in general payments reported to CMS, 2019-2025
8 companies · $7,100 in 2025
The $7,100 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $7,845 · 2021: $8,575 · 2022: $4,060 · 2023: $16K · 2024: $12K · 2025: $7,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,835 · Travel and Lodging: $2,655 · Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,372.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,835.00 |
| Travel and Lodging | $2,655.16 |
| Food and Beverage | $612.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58,966.58 | 2019-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $18,733.01 | 2019-2025 | |
| Array Biopharma INC | $7,410.19 | 2019-2025 | Braftovi, Mektovi |
| Incyte Corporation | $3,633.00 | 2019 | |
| Iovance Biotherapeutics, INC. | $84.90 | 2025 | Amtagvi |
| Seagen INC. | $13.62 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.